Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
about
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein ThrombosisControversies in the management of cancer-associated thrombosis.Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study.Retrievable Inferior Vena Cava Filters in Patients with Cancer: Complications and Retrieval Success Rate.A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment.Iliofemoral Venous Thrombosis Mainly Related to Iliofemoral Venous Obstruction by External Tumor Compression in Cancer Patients.Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study.Treating patients with cancer and acute venous thromboembolism.Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy.Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant.Peripherally inserted central catheters (PICCs) in cancer patients under chemotherapy: A prospective study on the incidence of complications and overall failures.Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice.Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins.The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants.Pharmacodynamic properties and bioequivalence of dalteparin sodium subcutaneous injection in healthy Chinese male subjects.Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options.COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional studyTreatment algorithm in cancer-associated thrombosis: Canadian expert consensus
P2860
Q26749273-8A20C931-7647-44C9-996B-1611EB9CAB45Q33436975-DF320779-4BAA-433F-8B77-F1DD2CE2B153Q33439387-13959F80-8DEF-4E14-B8D4-B12F691BD714Q36556204-45AAB5C3-5C1E-44E9-873F-00BDC37CE3A3Q37293267-1885281C-855D-48EB-A1B7-03FABC1F70EEQ37504333-E8A8F4D3-A091-49C8-B2EA-2F1FC5D5FBE9Q37653934-A9BCC404-167E-429A-B809-AAA4133EC1B9Q38647343-20BC5F63-19CE-4322-85C7-FD64E732AA60Q38686333-8C57E352-EF0C-4FB6-A4D8-0782FFB3BC3AQ39145374-EF366524-C464-4C25-9CEA-A370494103EAQ39884159-F0A3DC04-812A-42A3-9168-2BC28D9DF250Q40409105-DA4B21B3-0280-4EE3-B133-FAB3D70C1E7DQ47188579-3F3CC102-EE0A-4A41-93DA-A7AD743FA13AQ48948053-85A8428A-F44B-49DD-8FFE-8DFBBD0B0CD1Q50751188-01303BAB-2CCE-4CEF-936D-DFC0AE91FC49Q55364590-32C22160-9256-45DA-8007-D9519CD86DF6Q56515861-D0482617-BFD8-4329-B998-87E0964CBE0EQ59126194-05DC8C92-B92F-4922-8EBC-5FCEBA3C83A9
P2860
Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Treatment of venous thromboemb ...... 12 months: the DALTECAN Study.
@en
type
label
Treatment of venous thromboemb ...... 12 months: the DALTECAN Study.
@en
prefLabel
Treatment of venous thromboemb ...... 12 months: the DALTECAN Study.
@en
P2093
P2860
P356
P1476
Treatment of venous thromboemb ...... 12 months: the DALTECAN Study.
@en
P2093
A C Spyropoulos
A G Turpie
A K Kakkar
C M Kessler
C W Francis
D Bergqvist
I Pabinger
M J Kovacs
M V Huisman
P2860
P304
P356
10.1111/JTH.12923
P577
2015-05-10T00:00:00Z